JP2018148890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018148890A5 JP2018148890A5 JP2018076758A JP2018076758A JP2018148890A5 JP 2018148890 A5 JP2018148890 A5 JP 2018148890A5 JP 2018076758 A JP2018076758 A JP 2018076758A JP 2018076758 A JP2018076758 A JP 2018076758A JP 2018148890 A5 JP2018148890 A5 JP 2018148890A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- polypeptide
- seq
- protein
- vaccine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14191660 | 2014-11-04 | ||
| EP14191660.1 | 2014-11-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523902A Division JP6325751B2 (ja) | 2014-11-04 | 2015-11-03 | 治療用ｈｐｖ１６ワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018148890A JP2018148890A (ja) | 2018-09-27 |
| JP2018148890A5 true JP2018148890A5 (https=) | 2018-12-13 |
| JP6606571B2 JP6606571B2 (ja) | 2019-11-13 |
Family
ID=52020908
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523902A Active JP6325751B2 (ja) | 2014-11-04 | 2015-11-03 | 治療用ｈｐｖ１６ワクチン |
| JP2018076758A Active JP6606571B2 (ja) | 2014-11-04 | 2018-04-12 | 治療用ｈｐｖ１６ワクチン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523902A Active JP6325751B2 (ja) | 2014-11-04 | 2015-11-03 | 治療用ｈｐｖ１６ワクチン |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US9701721B2 (https=) |
| EP (2) | EP3421046A1 (https=) |
| JP (2) | JP6325751B2 (https=) |
| KR (1) | KR20170083562A (https=) |
| CN (1) | CN107075521B (https=) |
| AR (1) | AR102527A1 (https=) |
| AU (2) | AU2015341926B2 (https=) |
| BR (1) | BR112017009177A2 (https=) |
| CA (1) | CA2965562C (https=) |
| CL (1) | CL2017001089A1 (https=) |
| CO (1) | CO2017004838A2 (https=) |
| CY (1) | CY1121377T1 (https=) |
| DK (1) | DK3215187T3 (https=) |
| EA (1) | EA035461B1 (https=) |
| ES (1) | ES2697903T3 (https=) |
| HR (1) | HRP20181895T1 (https=) |
| HU (1) | HUE040440T2 (https=) |
| IL (1) | IL251895B (https=) |
| LT (1) | LT3215187T (https=) |
| MA (2) | MA40902B1 (https=) |
| MD (1) | MD3215187T2 (https=) |
| MX (1) | MX379069B (https=) |
| MY (1) | MY181175A (https=) |
| NZ (1) | NZ730802A (https=) |
| PL (1) | PL3215187T3 (https=) |
| PT (1) | PT3215187T (https=) |
| RS (1) | RS58080B1 (https=) |
| SA (1) | SA517381457B1 (https=) |
| SG (1) | SG11201702997YA (https=) |
| SI (1) | SI3215187T1 (https=) |
| SM (1) | SMT201800602T1 (https=) |
| TW (2) | TWI731654B (https=) |
| WO (1) | WO2016071306A1 (https=) |
| ZA (1) | ZA201703055B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58080B1 (sr) | 2014-11-04 | 2019-02-28 | Janssen Vaccines & Prevention Bv | Terapeutske vakcine protiv hpv16 |
| JP6470872B2 (ja) | 2015-08-20 | 2019-02-13 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 治療用ｈｐｖ１８ワクチン |
| JP7053491B2 (ja) * | 2016-05-02 | 2022-04-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 治療用ｈｐｖワクチン組み合わせ |
| CN106632694B (zh) * | 2017-01-24 | 2021-02-12 | 南京益康生物医药有限公司 | 一种重组蛋白及药物组合物与应用 |
| CA3058807A1 (en) | 2017-04-03 | 2018-10-11 | Biontech Us Inc. | Protein antigens and uses thereof |
| MX2020003071A (es) | 2017-09-23 | 2020-07-28 | Boehringer Ingelheim Vetmedica Gmbh | Sistema de expresion de paramyxoviridae. |
| WO2019164970A1 (en) * | 2018-02-20 | 2019-08-29 | Emory University | Hpv proteins, antibodies, and uses in managing abnormal epithelial cell growth |
| AU2019234549B2 (en) * | 2018-03-12 | 2026-02-12 | Sqz Biotechnologies Company | Methods for treating HPV-associated diseases |
| EP3810277A1 (en) * | 2018-07-20 | 2021-04-28 | Janssen Vaccines & Prevention B.V. | Recombinant adenoviral vector expressing zika antigen with improved productivity |
| CN108939064B (zh) * | 2018-08-06 | 2021-12-10 | 南京颂悦生物科技有限公司 | 基于重组减毒绵羊李斯特菌的宫颈癌治疗性疫苗 |
| CN108992665B (zh) * | 2018-08-06 | 2021-11-19 | 南京颂悦生物科技有限公司 | 基于重组减毒单增李斯特菌的宫颈癌治疗性疫苗 |
| EP3935581A4 (en) | 2019-03-04 | 2022-11-30 | Iocurrents, Inc. | DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING |
| US20230405105A1 (en) | 2019-09-20 | 2023-12-21 | Transgene Sa | Combination of a poxvirus encoding hpv polypeptides with an anti-pd-l1 antibody |
| WO2021202949A2 (en) * | 2020-04-02 | 2021-10-07 | Inovio Pharmaceuticals, Inc. | Compositions and methods for treating vulvar dysplasia |
| WO2021209897A1 (en) | 2020-04-13 | 2021-10-21 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
| US20210353744A1 (en) * | 2020-05-12 | 2021-11-18 | Janssen Vaccines Prevention B.V. | Administration of homologous adenoviral vectors |
| CA3200064A1 (en) * | 2020-11-24 | 2022-06-02 | Ma, Muchou Joe | Dna vaccine for human palillomavirus and method for using the same |
| JP2024539188A (ja) * | 2021-10-22 | 2024-10-28 | イノビオ ファーマシューティカルズ，インコーポレイティド | 肛門高悪性度扁平上皮内病変（ｈｓｉｌ）を治療するための組成物及び方法 |
| WO2025092908A1 (zh) * | 2023-11-01 | 2025-05-08 | 仁景(苏州)生物科技有限公司 | 治疗HPV感染相关疾病的mRNA疫苗 |
| CN120607593A (zh) * | 2024-03-06 | 2025-09-09 | 诺未生物技术(无锡)有限公司 | 治疗hpv感染相关疾病的药物 |
| CN118344491B (zh) * | 2024-05-03 | 2025-02-14 | 华中科技大学同济医学院附属同济医院 | 一种hpv16/18治疗性疫苗、制备方法和应用 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| ATE336587T1 (de) | 1994-06-10 | 2006-09-15 | Genvec Inc | Adenoviren-vektor systeme und zelllinien |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| IL160406A0 (en) | 1995-06-15 | 2004-07-25 | Crucell Holland Bv | A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| US5891690A (en) | 1996-04-26 | 1999-04-06 | Massie; Bernard | Adenovirus E1-complementing cell lines |
| CA2283253A1 (en) | 1997-03-04 | 1998-09-11 | Baxter International Inc. | Adenovirus e1-complementing cell lines |
| US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
| US5972650A (en) | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| ES2372823T3 (es) | 1999-05-17 | 2012-01-26 | Crucell Holland B.V. | Adenovirus recombinante del serotipo ad11. |
| WO2003104467A1 (en) | 2002-04-25 | 2003-12-18 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| FR2794370B1 (fr) | 1999-06-03 | 2003-10-17 | Biovector Therapeutics | Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
| CA2384987A1 (en) * | 1999-09-16 | 2001-03-22 | Zycos Inc. | Nucleic acids encoding polyepitope polypeptides |
| DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
| AU2002211490A1 (en) | 2000-10-04 | 2002-04-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| WO2002088346A2 (en) | 2001-05-01 | 2002-11-07 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
| SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| AU2005222776A1 (en) * | 2003-12-31 | 2005-09-29 | Genimmune N.V. | Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions |
| US20070207461A1 (en) | 2004-02-23 | 2007-09-06 | Crucell Holland B.V. | Virus Purification Methods |
| KR101271884B1 (ko) | 2004-11-08 | 2013-06-05 | 크로마제닉스 비.브이. | 고수준으로 단백질을 발현하는 숙주세포의 선택 |
| WO2007073513A2 (en) | 2005-11-10 | 2007-06-28 | Genvec, Inc. | Method for propagating adenoviral vectors encoding inhibitory gene products |
| CN103122360A (zh) | 2006-02-28 | 2013-05-29 | 瓦克萨特公司 | 嵌合腺病毒载体 |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| CL2008000249A1 (es) * | 2007-01-30 | 2008-05-30 | Transgene Sa | Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus |
| DE102008010954A1 (de) * | 2008-02-25 | 2009-08-27 | Cichon, Günter, Prof.Dr. | DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen |
| US10041049B2 (en) | 2008-11-03 | 2018-08-07 | Janssen Vaccines & Prevention B.V. | Method for the production of adenoviral vectors |
| GB0823497D0 (en) | 2008-12-24 | 2009-01-28 | Isis Innovation | Immunogenic composition and use thereof |
| MX2012007936A (es) | 2010-02-15 | 2012-11-22 | Crucell Holland Bv | Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus. |
| PL2604629T3 (pl) * | 2010-08-13 | 2018-08-31 | Genexine, Inc. | Kompozycja do zapobiegania lub leczenia raka szyjki macicy ze wzmacniaczem odporności przeciwko wirusowi brodawczaka ludzkiego |
| US20130122038A1 (en) | 2011-11-14 | 2013-05-16 | The United States Of America As Represented By The Secretary Of The Department | Heterologous prime-boost immunization using measles virus-based vaccines |
| EP2601968A1 (en) * | 2011-12-06 | 2013-06-12 | Deutsches Krebsforschungszentrum | HPV derived polynucleic acids for therapy |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
| EP3188752A2 (en) | 2014-09-03 | 2017-07-12 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
| RS58080B1 (sr) | 2014-11-04 | 2019-02-28 | Janssen Vaccines & Prevention Bv | Terapeutske vakcine protiv hpv16 |
| JP6470872B2 (ja) * | 2015-08-20 | 2019-02-13 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 治療用ｈｐｖ１８ワクチン |
| JP7053491B2 (ja) * | 2016-05-02 | 2022-04-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 治療用ｈｐｖワクチン組み合わせ |
-
2015
- 2015-11-03 RS RS20181369A patent/RS58080B1/sr unknown
- 2015-11-03 KR KR1020177014129A patent/KR20170083562A/ko not_active Abandoned
- 2015-11-03 CN CN201580060062.4A patent/CN107075521B/zh active Active
- 2015-11-03 EP EP18182588.6A patent/EP3421046A1/en not_active Withdrawn
- 2015-11-03 CA CA2965562A patent/CA2965562C/en active Active
- 2015-11-03 SI SI201530481T patent/SI3215187T1/sl unknown
- 2015-11-03 BR BR112017009177-1A patent/BR112017009177A2/pt not_active Application Discontinuation
- 2015-11-03 ES ES15791556T patent/ES2697903T3/es active Active
- 2015-11-03 MD MDE20170071T patent/MD3215187T2/ro not_active IP Right Cessation
- 2015-11-03 EA EA201790976A patent/EA035461B1/ru not_active IP Right Cessation
- 2015-11-03 MX MX2017005788A patent/MX379069B/es unknown
- 2015-11-03 LT LTEP15791556.2T patent/LT3215187T/lt unknown
- 2015-11-03 AU AU2015341926A patent/AU2015341926B2/en active Active
- 2015-11-03 HR HRP20181895TT patent/HRP20181895T1/hr unknown
- 2015-11-03 JP JP2017523902A patent/JP6325751B2/ja active Active
- 2015-11-03 MY MYPI2017701524A patent/MY181175A/en unknown
- 2015-11-03 DK DK15791556.2T patent/DK3215187T3/en active
- 2015-11-03 HU HUE15791556A patent/HUE040440T2/hu unknown
- 2015-11-03 PL PL15791556T patent/PL3215187T3/pl unknown
- 2015-11-03 SG SG11201702997YA patent/SG11201702997YA/en unknown
- 2015-11-03 SM SM20180602T patent/SMT201800602T1/it unknown
- 2015-11-03 NZ NZ730802A patent/NZ730802A/en not_active IP Right Cessation
- 2015-11-03 EP EP15791556.2A patent/EP3215187B1/en active Active
- 2015-11-03 WO PCT/EP2015/075516 patent/WO2016071306A1/en not_active Ceased
- 2015-11-03 PT PT15791556T patent/PT3215187T/pt unknown
- 2015-11-03 MA MA40902A patent/MA40902B1/fr unknown
- 2015-11-03 MA MA046378A patent/MA46378A/fr unknown
- 2015-11-04 US US14/932,789 patent/US9701721B2/en active Active
- 2015-11-04 TW TW109113009A patent/TWI731654B/zh not_active IP Right Cessation
- 2015-11-04 TW TW104136379A patent/TWI694147B/zh not_active IP Right Cessation
- 2015-11-04 AR ARP150103569A patent/AR102527A1/es not_active Application Discontinuation
-
2017
- 2017-04-25 IL IL251895A patent/IL251895B/en active IP Right Grant
- 2017-05-02 CL CL2017001089A patent/CL2017001089A1/es unknown
- 2017-05-03 SA SA517381457A patent/SA517381457B1/ar unknown
- 2017-05-03 ZA ZA201703055A patent/ZA201703055B/en unknown
- 2017-05-15 CO CONC2017/0004838A patent/CO2017004838A2/es unknown
- 2017-05-22 US US15/601,278 patent/US10071151B2/en active Active
-
2018
- 2018-04-12 JP JP2018076758A patent/JP6606571B2/ja active Active
- 2018-08-08 US US16/058,411 patent/US10555996B2/en active Active
- 2018-11-15 CY CY20181101210T patent/CY1121377T1/el unknown
- 2018-12-21 AU AU2018282463A patent/AU2018282463B2/en active Active
-
2020
- 2020-01-29 US US16/775,709 patent/US11040096B2/en active Active